Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | BTK inhibtors in CLL

Richard Furman • 10 Jun 2020
EHA 2020
B-Cell Lymphoma Chronic Lymphocytic Leukemia Leukemia Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Acalabrutinib Ibrutinib Nemtabrutinib Pirtobrutinib Vecabrutinib Zanubrutinib

Richard Furman, MD, of the Weill Cornell Medical College, New York, NY, updates us on the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL) as well as the development of third-generation BTK inhibitors that are currently in Phase II studies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Richard Furman

Combining B-cell receptor antagonists and venetoclax in CLL
2:46
Combining B-cell receptor antagonists and venetoclax in CLL
Richard Furman • 10 Jun 2020
Acalabrutinib monotherapy in mature B-cell malignancies
5:39
Acalabrutinib monotherapy in mature B-cell malignancies
Richard Furman • 10 Jun 2020
Diagnosis and Initial Treatment of CLL
17:52
Diagnosis and Initial Treatment of CLL
Peter Hillmen et al. • 12 May 2017

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals